National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America As Represented by the Department of Health

The United States of America As Represented by the Secretary of

The United States of America As Represented by the Secretary, Department

Teizo Yoshimura

Edward J Leonard

Ettore Appella

Kouji Matsushima

Stephen D Showalter

Elizabeth A Robinson

Joost Oppenheim

Joost J Oppenheim

Masaaki Yamada

Junichi Yamagishi

Ryuji Furuta

Alison H Skeel

Hidenobu Kamohara

Ettore Appela

The disclosure provides methods of modulating the activity of DDR1. Methods for screening for agents that activate DDR1 are disclosed. Methods for inducing the maturation of immature macrophages and immature dendritic cells are also disclosed. In addition, methods for increasing neutrophil activation using a DDR1 activating agent, and methods for increasing leukocyte migration using a DDR1 activating agent, are provided.

Use of discoidin domain receptor 1 (DDR1) and agents that affect the DDR1/collagen pathway

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. The cloning of full length cDNA for the peptide products is also provided, as well as recombinant methods for the production of monocyte chemoattractant products. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.

Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies thereto

An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Nucleic acids encoding a novel neutrophil chemotactic factor

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.

Human derived monocyte attracting purified peptide products useful in a

An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.

Method of treating inflammation with antibodies to neutrophil

Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.

Human derived monocyte attracting purified protein product useful in a

The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.

Antibodies specific for neutrophic chemotactic factor

Neutrophil chemotactic factor

Process for preparing human derived monocyte attracting purified peptide

A method of purifying macrophage stimulating protein. Antibodies to macrophage stimulating protein and a bioassay for the detection of antibodies which bind macrophage stimulating protein.

Antibodies to macrophage stimulating protein, bioassay and

An expression vector in which a DNA encoding a human neutrophil chemotactic factor polypeptide is inserted, a transformant (a host cell transformed with the expression vector), and a process for production of the said polypeptide by using the said transformant.

Growing community of inventors

Frederick, MD, United States of America

Teizo Yoshimura